USPTO serial 97009404
KNOA PHARMACEUTICALS
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- CASE, LEIGH CAROLINE
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with KNOA PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
STAMFORD, CT, US
Stamford, CT, US
Stamford, CT, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Fara S. Sunderji
Fara S. Sunderji DORSEY & WHITNEY LLP1301 Avenue of the AmericasFloor 13NEW YORK, NY 10019Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | A house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associated with Alcohol Cessation (IAAC), anaphylaxis; pharmaceuticals for use in the treatment of oncology conditions, specifically glioblastoma multiforme (GBM), non Hodgkin lymphoma, solid tumors, melanoma, chronic myelogenous leukemia, hemato-oncology, refractory/relapsed malignancies, alone or in combination with other agents; analgesics; pharmaceuticals, namely, opioid antagonists; syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; syringes filled with opioid antagonists; injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectors filled with opioid antagonists; injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectable pharmaceuticals, namely, opioid antagonists | ACTIVE | — |
| 042 | Pharmaceutical research and development | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by KNOA PHARMA LLC
- Other trademarks owned by Purdue Pharma L.P.
- Other trademarks owned by Purdue Pharma L.P.
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named KNOA PHARMACEUTICALS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 19, 2026 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Aug 3, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 3, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jun 16, 2026 | EWAF | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | — |
| Jun 16, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 16, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 16, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 5, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 5, 2026 | EX5G | SOU EXTENSION 5 GRANTED | — |
| May 5, 2026 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Apr 17, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 17, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 17, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 1, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 30, 2025 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jun 26, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 25, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jun 25, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jun 25, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Mar 3, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 13, 2024 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Dec 13, 2024 | EXT3 | SOU EXTENSION 3 FILED | — |
| Dec 13, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 25, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 25, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 25, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 25, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 21, 2023 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 19, 2023 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Dec 19, 2023 | EXT1 | SOU EXTENSION 1 FILED | — |
| Dec 19, 2023 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 27, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 2, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| May 2, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 12, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 27, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 16, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 16, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 16, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 16, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 7, 2023 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Dec 27, 2022 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Dec 15, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 7, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 7, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 7, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 14, 2022 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 14, 2022 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 14, 2022 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Jun 7, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 15, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 6, 2021 | NWAP | NEW APPLICATION ENTERED | — |